Precision BioSciences, Inc. (NASDAQ:DTIL – Get Rating) has received an average rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $18.00.
Several equities analysts have recently commented on the stock. The Goldman Sachs Group reduced their price target on shares of Precision BioSciences from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 16th. Zacks Investment Research cut shares of Precision BioSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 19th.
In other Precision BioSciences news, CFO John Alexander Kelly bought 16,677 shares of the business’s stock in a transaction on Thursday, March 17th. The shares were purchased at an average price of $3.08 per share, with a total value of $51,365.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 13.80% of the company’s stock.
Shares of DTIL stock opened at $2.67 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.50 and a current ratio of 4.50. Precision BioSciences has a one year low of $2.57 and a one year high of $14.38. The company’s 50-day simple moving average is $3.70 and its 200-day simple moving average is $6.69. The stock has a market capitalization of $162.98 million, a price-to-earnings ratio of -4.94 and a beta of 1.64.
Precision BioSciences Company Profile (Get Rating)
Precision BioSciences, Inc, a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
- Get a free copy of the StockNews.com research report on Precision BioSciences (DTIL)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.